Elusive EU Clinical Trial Rules Slip Again – Now To Late 2018
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA board says it's "critical" that the complex new program provides the "required functionalities to all stakeholders in the most efficient and stable way from the start of its operations."
You may also be interested in...
Yet Another Delay For Landmark EU Clinical Trial Rules – Now To 2019
The go-live date for the coming EU Clinical Trial Regulation and accompanying portal and database is being postponed again. The delay will also impact the EMA’s schedule for training drug sponsors and European authorities in how to use the portal and database.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.